Free Trial

Krystal Biotech (KRYS) Stock Price, News & Analysis

$166.62
+2.17 (+1.32%)
(As of 03:58 PM ET)
Today's Range
$162.74
$166.91
50-Day Range
$153.12
$180.42
52-Week Range
$93.95
$189.97
Volume
147,435 shs
Average Volume
347,136 shs
Market Capitalization
$4.76 billion
P/E Ratio
89.10
Dividend Yield
N/A
Price Target
$171.00

Krystal Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.1% Upside
$177.63 Price Target
Short Interest
Bearish
9.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.42mentions of Krystal Biotech in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$6.21 M Sold Last Quarter
Proj. Earnings Growth
110.19%
From $2.06 to $4.33 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

90th out of 921 stocks

Biological Products, Except Diagnostic Industry

8th out of 152 stocks

KRYS stock logo

About Krystal Biotech Stock (NASDAQ:KRYS)

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS Stock Price History

KRYS Stock News Headlines

See More Headlines
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
5/21/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
229
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$177.63
High Stock Price Target
$204.00
Low Stock Price Target
$153.00
Potential Upside/Downside
+3.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$10.93 million
Pretax Margin
61.62%

Debt

Sales & Book Value

Annual Sales
$50.70 million
Book Value
$27.60 per share

Miscellaneous

Free Float
24,531,000
Market Cap
$4.74 billion
Optionable
Optionable
Beta
0.91

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

KRYS Stock Analysis - Frequently Asked Questions

Should I buy or sell Krystal Biotech stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings
or view top-rated stocks.

What is Krystal Biotech's stock price target for 2024?

9 brokerages have issued 12-month target prices for Krystal Biotech's shares. Their KRYS share price targets range from $153.00 to $204.00. On average, they expect the company's stock price to reach $177.63 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for KRYS
or view top-rated stocks among Wall Street analysts.

How have KRYS shares performed in 2024?

Krystal Biotech's stock was trading at $124.06 at the beginning of the year. Since then, KRYS stock has increased by 33.7% and is now trading at $165.81.
View the best growth stocks for 2024 here
.

When is Krystal Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our KRYS earnings forecast
.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) announced its quarterly earnings data on Monday, May, 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by $0.17. The firm had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. The company's revenue was up 452400.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.76) EPS.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (8.95%), Vanguard Group Inc. (8.52%), Redmile Group LLC (5.28%), Jennison Associates LLC (2.35%), Price T Rowe Associates Inc. MD (2.31%) and Hood River Capital Management LLC (1.74%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends
.

How do I buy shares of Krystal Biotech?

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRYS) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners